195 related articles for article (PubMed ID: 29567511)
41. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
[TBL] [Abstract][Full Text] [Related]
42. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
43. Structure, expression and function of HLA-G in renal cell carcinoma.
Seliger B; Schlaf G
Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
[TBL] [Abstract][Full Text] [Related]
44. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance.
Loumagne L; Baudhuin J; Favier B; Montespan F; Carosella ED; Rouas-Freiss N
Int J Cancer; 2014 Nov; 135(9):2107-17. PubMed ID: 24623585
[TBL] [Abstract][Full Text] [Related]
45. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
46. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
Garrido F; Cabrera T; Aptsiauri N
Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
[TBL] [Abstract][Full Text] [Related]
47. Editorial: Tissue Resident Memory T Cells.
Mami-Chouaib F; Tartour E
Front Immunol; 2019; 10():1018. PubMed ID: 31191515
[No Abstract] [Full Text] [Related]
48. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
50. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.
Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P
J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488
[TBL] [Abstract][Full Text] [Related]
51. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
[TBL] [Abstract][Full Text] [Related]
52. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma.
Oldford SA; Robb JD; Watson PH; Drover S
Int J Cancer; 2004 Nov; 112(3):399-406. PubMed ID: 15382064
[TBL] [Abstract][Full Text] [Related]
53. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
54. The urgent need to recover MHC class I in cancers for effective immunotherapy.
Garrido F; Aptsiauri N; Doorduijn EM; Garcia Lora AM; van Hall T
Curr Opin Immunol; 2016 Apr; 39():44-51. PubMed ID: 26796069
[TBL] [Abstract][Full Text] [Related]
55. T-cell immunometabolism against cancer.
Jiang S; Yan W
Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
[TBL] [Abstract][Full Text] [Related]
56. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?
Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED
Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995
[TBL] [Abstract][Full Text] [Related]
57. Tissue-Resident Memory T Cells in Cancer Immunosurveillance.
Park SL; Gebhardt T; Mackay LK
Trends Immunol; 2019 Aug; 40(8):735-747. PubMed ID: 31255505
[TBL] [Abstract][Full Text] [Related]
58. Tumor infiltrating lymphocytes in HLA+ and HLA- laryngeal cancer--quantitative approach.
Dworacki G; Kruk-Zagajewska A; Jezewska E; Sikora J; Zeromski J
Arch Immunol Ther Exp (Warsz); 1999; 47(3):161-8. PubMed ID: 10470443
[TBL] [Abstract][Full Text] [Related]
59. The HLA crossroad in tumor immunology.
Algarra I; Cabrera T; Garrido F
Hum Immunol; 2000 Jan; 61(1):65-73. PubMed ID: 10658979
[TBL] [Abstract][Full Text] [Related]
60. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
